Welcome to our dedicated page for VVY news (Ticker: vvy), a resource for investors and traders seeking the latest updates and insights on VVY stock.
Vivoryon Therapeutics N.V. (VVY) is a clinical-stage biopharmaceutical company advancing novel therapies for kidney diseases and neurodegenerative disorders. This page aggregates official press releases and verified news about clinical trial progress, regulatory milestones, and strategic partnerships.
Investors and researchers will discover timely updates on therapeutic candidates, including detailed analyses of clinical endpoints like eGFR measurements in kidney studies. Content spans trial phase results, peer-reviewed research collaborations, and financial reporting.
Key categories include clinical development updates, regulatory communications, and scientific partnership announcements. All materials are sourced directly from the company or reputable financial/news outlets to ensure accuracy.
Bookmark this page for streamlined access to Vivoryon's latest developments, presented with context for both medical professionals and investment analysts. Check regularly for updates on pipeline advancements and data disclosures.
Vivoryon Therapeutics N.V. announces participation in two key investor conferences:
- Van Lanschot Kempen Life Sciences Conference on April 25-26, 2023, featuring one-on-one meetings in Amsterdam.
- Bio€quity Europe on May 14-16, 2023, with a presentation scheduled for May 16, 2023, at 10:44 am IST in Dublin.
As a clinical-stage biotechnology company, Vivoryon focuses on developing small molecule medicines aimed at modulating pathologically altered proteins, including its lead program, varoglutamstat, which targets Alzheimer’s disease in Phase 2 clinical development. The company is committed to advancing treatments for severe diseases, utilizing extensive expertise in protein modifications.
Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY) reported its full-year 2022 financial results, highlighting advancements in clinical trials for varoglutamstat, a potential treatment for Alzheimer’s disease. The VIVIAD and VIVA-MIND studies progressed significantly, with final data from VIVIAD expected in Q1 2024 and a clinical update on VIVA-MIND anticipated in 2H 2023. The company bolstered its financial position with two successful private placements totaling EUR 36 million, with an option for up to an additional EUR 15 million. Despite a net loss of EUR 28.2 million in 2022, an increase from EUR 12.7 million in 2021, the cash balance at year-end stood at EUR 26.6 million, supporting operations through at least December 2023. Management is optimistic about ongoing trials and the potential for future partnerships.
Vivoryon Therapeutics N.V. will report its full year 2022 financial results and operational progress on April 19, 2023. The conference call is scheduled for 03:00 pm CEST / 09:00 am EDT and will be available via phone and webcast. The report will be accessible on their website. Vivoryon is dedicated to developing small molecule medicines aimed at modulating altered proteins in various diseases, including a lead program in Phase 2 clinical trials for Alzheimer’s disease. The company is also advancing a solid pipeline of molecules targeting other conditions such as cancer and fibrosis.
